Effect of smoking cessation on multiple sclerosis prognosis

JAMA Neurology

Volumn 72, Issue 10, 2015, Pages 1117-1123

  Ramanujam, Ryan ^a,b   Hedström, Anna Karin ^c   Manouchehrinia, Ali ^a   Alfredsson, Lars ^c,d   Olsson, Tomas ^a   Bottai, Matteo ^c   Hillert, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d STOCKHOLM COUNTY COUNCIL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REGISTER; SEX; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; SWEDEN; ADVERSE EFFECTS; DISEASE COURSE; MIDDLE AGED; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGNOSIS; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 84944069641     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.1788     Document Type: Article

References (33)

1. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler. 2011;17(8):901-908.
2. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004-2015.
3. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-647.
4. Castrop F, Haslinger B, Hemmer B, Buck D. Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta. Neuropsychiatr Dis Treat. 2013;9:1339-1349.
5. Newton AN, Stica CM. A comprehensive cost-effectiveness analysis of treatments for multiple sclerosis. Int J MS Care. 2011;13(3):128-135.
6. Wipfli H, Samet JM. Global economic and health benefits of tobacco control: part 1. Clin Pharmacol Ther. 2009;86(3):263-271.
7. Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult Scler. 2007;13(5):610-615.
8. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology. 2009;73(9):696-701.
9. Handel AE, Williamson AJ, Disanto G, Dobson R, Giovannoni G, Ramagopalan SV. Smoking and multiple sclerosis: an updated meta-analysis. PLoS One. 2011;6(1):e16149.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
11. Hedström A, Hillert J, Olsson T, Alfredsson L. Smoking and multiple sclerosis susceptibility. Eur J Epidemiol. 2013;28(11):867-874.
12. Burney PGJ, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. Eur Respir J. 1994;7(5):954-960.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452.
14. R Development Core Team. R: A Language and Environment for Statistical Computing. 2014. http://www.r-project.org/. Accessed March 27, 2015.
15. StataCorp. Stata Statistical Software: Release 13. 2015.
16. Koch M, Van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology. 2007;69(15):1515-1520.
17. Hernán MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain. 2005;128(pt 6):1461-1465.
18. Healy BC, Ali E, Guttmann CR, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009;66(7):858-864.
19. Sundström P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler. 2008;14(8):1031-1035.
20. Correale J, Farez MF. Smoking worsens multiple sclerosis prognosis: two different pathways are involved. J Neuroimmunol. 2015;281:23-34.
21. Törner A, Duberg A-S, Dickman P, Svensson A. A proposed method to adjust for selection bias in cohort studies. Am J Epidemiol. 2010;171(5):602-608.
22. Orbe J, Ferreira E, Núñez-Antón V. Comparing proportional hazards and accelerated failure time models for survival analysis. Stat Med. 2002;21(22):3493-3510.
23. Kwidzinski E, Bunse J, Aktas O, et al. Indolamine 2, 3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J. 2005;19(10):1347-1349.
24. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis. 1997;56(8):463-469.
25. Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 1998;57(8):451-455.
26. Shirani A, Tremlett H. The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res. 2010;3:115-126.
27. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012;5(1):13-22.
28. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247-256.
29. Ebers GC, Traboulsee A, Li D, et al; Investigators of the 16-year Long-Term Follow-up Study. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010;81(8):907-912.
30. Sawcer S, Hellenthal G, Pirinen M, et al; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
31. Beecham AH, Patsopoulos NA, Xifara DK, et al; International Multiple Sclerosis Genetics Consortium (IMSGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45(11):1353-1360.
32. Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler. 2008;14(5):679-690.
33. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ. 2006;7 (2) (suppl 2):S96-S104.